New drug wafer aims to block lung Cancer's return
NCT ID NCT06693336
Summary
This study is testing a new drug called SMS001, which is a special form of the chemotherapy paclitaxel. It is being given to patients with early-stage non-small cell lung cancer right after their surgery, with the goal of preventing the cancer from coming back. Researchers will check if the treatment is safe and see how many patients remain cancer-free one year later.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.